NDA 020241 · Glaxosmithkline LLC
Lamictal
Lamotrigine · Oral · Anti-epileptic Agent; Mood Stabilizer
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Oct 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Dec 27, 1994
Approved uses
9
Original approval plus efficacy supplements
Registered trials
191
49 Phase 3, 8 recruiting
FAERS reports
131,733
95,211 serious, 11,487 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS SKIN RASHES LAMICTAL can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 to 17 years) and 0.08% to 0.3% in adults receiving LAMICTAL. One rash-related death was reported in a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking LAMICTAL as adjunctive therapy. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate. In addition to age, factors that may increase the risk of occurrence or the severity of rash caused by LAMICTAL include (1) coadministration of LAMICTAL with valproate...
What it is approved for
From the label in effect Oct 10, 2025.
LAMICTAL is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: • partial-onset seizures. • primary generalized tonic-clonic (PGTC) seizures. • generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of LAMICTAL in the acute treatment of mood episodes has not been established. 1.1 Epilepsy Adjunctive Therapy LAMICTAL is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: • partial-onset seizures. • primary generalized tonic-clonic (PGTC) seizures. • generalized seizures of Lennox-Gastaut syndrome. Monotherapy LAMICTAL is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of LAMICTAL have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder LAMICTAL is indicated for the maintenance treatment of bipolar I disorder to delay the time...
Mechanism: The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human epilepsy,...
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 18, 2015 Supplement 53 · Efficacy LabelLetter
- Sep 22, 2006 Supplement 27 · Efficacy ReviewLabelLetter
- Jan 14, 2004 Supplement 16 · Efficacy Letter
- Jun 20, 2003 Supplement 17 · Efficacy ReviewLetterLabel
- Jan 17, 2003 Supplement 8 · Efficacy Label
- May 25, 2001 Supplement 11 · Efficacy ReviewLabel
- Dec 14, 1998 Supplement 3 · Efficacy LetterReviewLabel
- Aug 24, 1998 Supplement 2 · Efficacy ReviewLabelLetter
- Dec 27, 1994 Original approval · Type 1 - New Molecular Entity · priority review
6 products under this application
- LAMICTAL · LAMOTRIGINE 150MG · TABLET, ORAL · Prescription · TE AB
- LAMICTAL · LAMOTRIGINE 25MG · TABLET, ORAL · Prescription · TE AB
- LAMICTAL · LAMOTRIGINE 200MG · TABLET, ORAL · Prescription · TE AB
- LAMICTAL · LAMOTRIGINE 100MG · TABLET, ORAL · Prescription · TE AB
- LAMICTAL · LAMOTRIGINE 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- LAMICTAL · LAMOTRIGINE 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Lamotrigine" as an intervention, any sponsor and status, largest first.
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
GlaxoSmithKlineGSK (GSK)
NCT00067938 · 1,200 participants · Start Aug 2003 · Primary completion Aug 2004
Drug: lamotrigine · For: Bipolar Disorder
Sites: Albertville, Alabama; Anniston, Alabama; Birmingham, Alabama · 308 sites in all
- A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed EpisodePivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00277212 · 1,169 participants · Start Dec 1, 2005 · Primary completion Jul 1, 2009
Drug: Lamotrigine + Aripiprazole; Lamotrigine + Placebo · For: Bipolar Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; Anaheim, California · 66 sites in all
- Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.Pivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00007670 · 720 participants · Start Jan 1998
Drug: Carbamazepine; Gabapentin and 1 more · For: Seizures
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 20 sites in all
- Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder PatientsPivotal-lookingTerminated
Ministry of Health & Welfare, KoreaGovernment (non-federal)
NCT00926835 · 692 participants · Start May 2009 · Primary completion May 2015
Drug: paroxetine; Escitalopram and 7 more · For: Major Depressive Disorder
Sites: Seoul, South Korea
- Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial EpilepsyPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00280059 · 660 participants · Start Aug 2006 · Primary completion Dec 2009
Drug: Pregabalin; Lamotrigine · For: Epilepsy, Partial
Sites: Bruges, Belgium; Brussels, Belgium; Leuven, Belgium · 102 sites in all
- Modality Choice Before and After Failure for the Treatment of Painful Diabetic NeuropathyPivotal-lookingNot yet recruiting
University of MichiganAcademic, hospital or other
NCT07795593 · 600 participants (planned) · Start Nov 2026 · Primary completion May 2031
Drug: Oral Medication; Topical Medication · For: Painful Diabetic Neuropathy (PDN); Diabetic Nephropathies
Sites: Stanford, California; Jacksonville, Florida; Chicago, Illinois · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective10,332
- rash8,688
- seizure6,701
- nausea6,455
- off label use6,291
- fatigue6,259
- dizziness6,075
- headache5,812
- depression5,269
- vomiting4,846
- somnolence4,541
- pyrexia4,521
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2,016 |
| 2005 | 3,052 |
| 2006 | 3,557 |
| 2007 | 3,880 |
| 2008 | 2,377 |
| 2009 | 4,888 |
| 2010 | 3,756 |
| 2011 | 4,923 |
| 2012 | 5,255 |
| 2013 | 4,635 |
| 2014 | 5,128 |
| 2015 | 7,165 |
| 2016 | 7,472 |
| 2017 | 7,202 |
| 2018 | 8,195 |
| 2019 | 8,572 |
| 2020 | 7,702 |
| 2021 | 7,239 |
| 2022 | 6,628 |
| 2023 | 6,979 |
| 2024 | 7,673 |
| 2025 | 7,869 |
| 2026 | 5,569 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lamictal (Lamotrigine)
2024 spending
$60.1M
Beneficiaries
5,504
43,491 claims
Per beneficiary
$10,918
$11.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $103,289,398 |
| 2021 | $103,590,575 |
| 2022 | $108,690,543 |
| 2023 | $111,836,411 |
| 2024 | $60,092,658 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures.
Bresnahan R, Panebianco M, Marson AG · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Yildiz A, Siafis S, Mavridis D, et al. · Lancet Psychiatry 2023 · Systematic Review, Network Meta-Analysis
- The efficacy of lamotrigine in bipolar disorder: A systematic review and meta-analysis.
Haenen N, Kamperman AM, Prodan A, et al. · Bipolar Disord 2024 · Systematic Review, Meta-Analysis
- Acute lamotrigine overdose: a systematic review of published adult and pediatric cases.
Alyahya B, Friesen M, Nauche B, et al. · Clin Toxicol (Phila) 2018 · Systematic Review
- Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis.
Chu H, Zhang X, Shi J, et al. · J Neurol 2023 · Systematic Review, Network Meta-Analysis
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.